Merck & Co. (NYSE:MRK) and Gilead Sciences Inc. (NYSE:GILD) are two pharmaceutical heavyweights whose stocks tell very ...

Gilead Sciences Inc. closed $8.74 short of its 52-week high ($87.87), which the company achieved on January 19th.

Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program ...

Biotech giant Gilead Sciences, Inc. GILD has gained 16.8% in the past three months compared with the industry’s growth of 7.6 ...

Very pleased to be hosting Gilead this afternoon, sorry. And we have joining us Dan O'Day, the company's Chairman and CEO; and Andy Dickinson, the company's CFO. Thank you both for taking time out of ...

Mohit Bansal, an analyst from Wells Fargo, maintained the Hold rating on Gilead Sciences (GILD – Research Report). The associated price ...

Gilead Sciences Inc. closed $8.17 short of its 52-week high ($87.87), which the company reached on January 19th.

Since my last article, Gilead Sciences, Inc.'s stock price has continued to rise, thanks in part to strong sales of its HIV ...

Here, Johanna Mercier, Chief Commercial Officer, shares how Gilead works to help remove barriers to care, improve health equity and increase access to life-changing therapies – all of which underscore ...

Financial giants have made a conspicuous bearish move on Gilead Sciences. Our analysis of options history for Gilead Sciences ...

Avenzo Therapeutics has announced a clinical trial partnership and supply agreement with Gilead Sciences to assess a ...

After dropping the first set against visiting Plymouth Tuesday, the Mount Gilead volleyball rallied to earn its first win of the season. Plymouth took the first set 25-14, but the Indians stormed back ...